Clinical Trial Update: A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of GSK2485852 in chronically infected Hepatitis C patients has been terminated. The study assessed safety, tolerability, pharmaco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK2485852

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis C | Phase 1 | Status: TERMINATED